Updates on RAD51C, RAD51D, and BRIP1

Value of the Information & Strength of the Argument

The video provides valuable, up-to-date information on the cancer risks associated with RAD51C, RAD51D, and BRIP1, synthesizing recent studies and an ACMG clinical practice resource. The argumentation is solid, grounded in peer-reviewed literature and expert consensus. The speaker clearly explains the evolution of risk estimates and the importance of individualized risk assessment, using case examples and data from key studies. The presentation is well-structured, moving from background to clinical management, and addresses practical challenges in counseling. The discussion of the case adds a practical dimension, illustrating how these risks are applied in a real clinical scenario.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to multiple peer-reviewed studies and an ACMG clinical practice resource. The speaker is a recognized expert in clinical genetics, and the content aligns with current guidelines. The title accurately reflects the content, focusing on updates for these three genes. The video is an expert opinion and not a systematic review, but it is based on a thorough review of the literature. The sources are credible and relevant, and the presentation is balanced, acknowledging uncertainties and the need for individualized care.

The title accurately reflects the content, which focuses on updates for these three genes.

8/10

Presentation by a clinical genetics expert, based on recent literature and an ACMG clinical practice resource, with clear references to studies. However, it is an expert opinion and not a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and case presentation of a 42-year-old woman with a BRIP1 variant.
• 03:00Discussion of the case and initial management recommendations.
• 07:00Dr. Hanson begins her presentation on RAD51C, RAD51D, and BRIP1.
• 10:00Overview of the discovery of these genes and their association with Fanconi anemia.
• 13:00Discussion of breast cancer risk for RAD51C and RAD51D, including recent studies.
• 16:00Discussion of BRIP1 and its association with ovarian cancer.
• 19:00Summary of cancer risks and the importance of individualized risk assessment.
• 22:00Ovarian cancer risk management recommendations, including risk-reducing surgery.
• 25:00Breast cancer management and the role of risk-reducing mastectomy.
• 28:00Challenges in counseling and take-home messages.

• ACMG clinical practice resource for RAD51C, RAD51D, and BRIP1 — Mentioned as recently published and co-led by Dr. Hanson.
• Study by Cummings et al. on age of onset in carriers identified through multi-gene panel testing — Cited for median age of onset of ovarian cancer in BRIP1 carriers.
• Study by Yangatau et al. on families with RAD51C and RAD51D — Cited for breast and ovarian cancer risks in these families.
• Study by Darling et al. (2021) on breast cancer subtypes — Cited for association with ER-negative/triple-negative breast cancer.
• Study by Sunatau et al. (2015) on unselected ovarian cancer cases — Cited for confirming moderate-risk ovarian cancer predisposition.
• Study by Gareth Evans group in Manchester — Cited for demonstrating BRIP1 as the third most important ovarian cancer gene.
• Study by Susan Ramos et al. (2005) on BRIP1 and ovarian cancer — Cited for association of BRIP1 with ovarian cancer.
• Study by Doug Easton's group — Cited for weak association of BRIP1 with breast cancer.
• Study by CLA Turnbull's group (meta-analysis) — Cited for lower odds ratio for breast cancer in RAD51C/D.
• JCO paper on risk-reducing salpingo-oophorectomy thresholds — Cited for 3-4% and 5% risk thresholds.
• Bodisa or CanRisk paper — Cited for individualized risk assessment with modifying factors.

• NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic — Provides clinical management recommendations for these genes.
• NICE guidance on familial breast cancer — UK guidelines for breast cancer risk management.

• www.linkedin.com